Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDNF | P23560 | 3/20 | 0.42 |
| ▸ | PTN | P21246 | 2/20 | 0.42 |
| ▸ | MDK | P21741 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
| ▸ | SELP | P16109 | 3/20 | 0.36 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.35 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.35 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.35 |
| ▸ | BMP2 | P12643 | 1/20 | 0.33 |
| ▸ | VEGFA | P15692 | 1/20 | 0.33 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.33 |
| ▸ | SHH | Q15465 | 1/20 | 0.33 |
| ▸ | B4GALT1 | P15291 | 1/20 | 0.33 |
| ▸ | IGF2R | P11717 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17210591 | 0.91 | BDNF (0.45) | BDNFPTNMDKMAPK1SELP | |
| SCHEMBL17210625 | 0.89 | MAPK1 (0.54) | BDNFPTNMDKMAPK1CA1 | |
| SCHEMBL17208461 | 0.80 | MAPK1 (0.64) | BDNFPTNMDKMAPK1CA1 | |
| SCHEMBL17208463 | 0.80 | MAPK1 (0.64) | BDNFPTNMDKMAPK1CA1 | |
| SCHEMBL17091478 | 0.80 | MAPK1 (0.63) | BDNFPTNMDKMAPK1CA1 | |
| SCHEMBL17210569 | 0.80 | IGF2R (0.38) | BDNFPTNMDKCA1CA2 | |
| SCHEMBL16694650 | 0.78 | MAPK1 (0.67) | MAPK1CA1CA2CA9SELP | |
| SCHEMBL17091458 | 0.78 | MAPK1 (0.67) | MAPK1CA1CA2CA9SELP | |
| SCHEMBL17091464 | 0.78 | MAPK1 (0.67) | MAPK1CA1CA2CA9SELP | |
| SCHEMBL17210593 | 0.74 | MAPK1 (0.73) | MAPK1CA1CA2CA9LGALS8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150307539-A1 | USE OF SULPHATED GLYCOLIPIDS AS PROMOTERS OF NEURITIC GROWTH, MYELINATION AND INHIBITING THE PROLIFERATION OF ASTROGLIA AND MICROGLIA | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) | 2015-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307539-A1 | USE OF SULPHATED GLYCOLIPIDS AS PROMOTERS OF NEURITIC GROWTH, MYELINATION AND INHIBITING THE PROLIFERATION OF ASTROGLIA AND MICROGLIA | BDNF, MAG, NTRK2 | BDNF 1/4885PTN 771/4885MDK 2406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.